Bank Of Montreal Liquidia Corp Transaction History

Bank Of Montreal

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$5.77 - $12.19 $42,726 - $90,266	7,405 Added 11.28%	73,030 $878,000
Q3 2023 Nov 01, 2023	SELL	$6.27 - $8.15 $332 - $431	-53 Reduced 0.08%	65,625 $416,000
Q2 2023 Aug 02, 2023	BUY	$6.63 - $9.9 $231,254 - $345,312	34,880 Added 113.25%	65,678 $515,000
Q1 2023 Jun 13, 2024	BUY	$5.72 - $7.91 $297,548 - $411,470	52,019 New	52,019 $359,000
Q4 2022 Feb 01, 2023	BUY	$4.68 - $6.54 $80,954 - $113,128	17,298 Added 128.13%	30,798 $196,000
Q3 2022 Nov 10, 2022	BUY	$3.73 - $8.39 $50,355 - $113,265	13,500 New	13,500 $75,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.